A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

Inclusion Criteria

• •The patient has completed the 16026A study and has received the last study treatment within 12 months of the screening visit for the present study.
• •The patient has an MRI scan done in relation to study 16026A performed within 9 months before first study visit in the extension study.
• •The patient has a knowledgeable and reliable caregiver/ study partner who will be available and able to accompany the patient to clinical visits, monitor Immunisation-Related Events after each immunisation, and participate with the patient at phone visits during the study